Why Clinical Trial Enrollment Matters in the Fight Against Cancer

Watch the first part of this interview.

In this video, Ravi Salgia, MD, PhD, thoracic medical oncologist and chair of Medical Oncology at City of Hope, speaks directly to fellow oncologists about enrolling patients in a new clinical trial. Any physician treating a newly diagnosed patients with metastatic non–small cell lung cancer without a targetable mutation like EGFR, ALK, or ROS1 is encouraged to consider referral.

Dr Salgia outlines the trial's national footprint, with sites across Southern California as well as in Chicago, Atlanta, and Phoenix, and touches on the broader ARPA-H ADAPT program, which is applying similar biomarker strategies to breast and colon cancer. He closes with a wider message to the field: sustained investment in research and mentorship of the next generation of physician-scientists as essential to translating trials like this one into cures.